Teprotumumab for the treatment of thyroid eye disease: The Holy grail, really?

被引：1
|
作者：
Martel, A. [1 ]
机构：
[1] Cote Azur Univ, Univ Hosp Nice, Ophthalmol Dept, 30, voie Romaine, F-06000 Nice, France
来源：
JOURNAL FRANCAIS D OPHTALMOLOGIE | 2023年 / 46卷 / 06期
关键词：
GRAVES ORBITOPATHY; RITUXIMAB;
D O I：
10.1016/j.jfo.2023.01.003
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：567 / 570
页数：4
相关论文
共 50 条
  • [41] Retinal Surface Macrophage Changes in Thyroid Eye Disease before and after Treatment with Teprotumumab
    Otero-Marquez, Oscar
    Fayad, Mona
    Pinhas, Alexander
    Chui, Toco Y. P.
    Rosen, Richard B. B.
    Reddy, Harsha S. S.
    CASE REPORTS IN OPHTHALMOLOGICAL MEDICINE, 2022, 2022
  • [42] The role of teprotumumab in chronic, clinically active thyroid eye disease
    Yu, Caroline Y.
    Simmons, Brittany A.
    Pham, Chau M.
    Shriver, Erin M.
    EYE, 2022, 36 (07) : 1500 - 1501
  • [43] A Prospective Study Examining Audiometry Outcomes Following Teprotumumab Treatment for Thyroid Eye Disease
    Douglas, Raymond S.
    Parunakian, Emanuil
    Tolentino, Joseph
    Malkhasyan, Emil
    Geng, June
    Sherman, Michele
    Ugradar, Shoaib
    THYROID, 2024, 34 (01) : 134 - 137
  • [44] Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab
    Ho, Tiffany C.
    Maamari, Robi N.
    Kossler, Andrea L.
    Sears, Connie M.
    Freitag, Suzanne K.
    Reshef, Edith R.
    Shinder, Roman
    Rootman, Daniel B.
    Diniz, Stefania B.
    Kahana, Alon
    Schlachter, Dianne
    Do, Thai H.
    Kally, Peter
    Turner, Sara
    Mokhtarzadeh, Ali
    Harrison, Andrew R.
    Hwang, Christopher J.
    Kim, Hee Joon
    Avila, Sarah A.
    Thomas, Dilip A.
    Magazin, Maja
    Wester, Sara T.
    Lee, Wendy W.
    Clauss, Kevin D.
    Holds, John B.
    Sniegowski, Matthew
    Compton, Christopher J.
    Briggs, Christian
    Malik, Amina I.
    Lucarelli, Mark J.
    Burkat, Cat N.
    Patel, Luv G.
    Couch, Steven M.
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2023, 39 (02): : 150 - 155
  • [45] Refractory Thyroid Eye Disease Unresponsive to Teprotumumab: A Case Report
    Singh, Gurdeep
    Taylor, Brittany
    Michalek, Samantha
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [46] Teprotumumab in thyroid eye disease: wonder drug or great divider?
    Perros, Petros
    Hegedus, Laszlo
    EUROPEAN THYROID JOURNAL, 2023, 12 (04)
  • [47] Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab
    Ugradar, Shoaib
    Braun, Jenna
    Wang, Yao
    Zimmerman, Erin
    Douglas, Raymond S.
    PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN, 2021, 9 (09) : E3809
  • [48] Teprotumumab for thyroid eye disease: early response is not required for benefit
    Shoaib Ugradar
    Yao Wang
    Tunde Mester
    George J. Kahaly
    Raymond S. Douglas
    Eye, 2022, 36 : 1403 - 1408
  • [49] Evaluation of the efficacy, safety, and durability of teprotumumab in thyroid eye disease
    Mechels, Keegan
    Hwang, Catherine
    Perry, Julian
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [50] The Effect of Teprotumumab on Ocular Surface Symptoms in Thyroid Eye Disease
    Cale, Mario
    Osias, Ethan
    Singh, Pallavi
    Rootman, Daniel
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
12345